IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of HANNA et al. Group Art Unit: 1644

Application Serial No. 09/772,938 Examiner: Phillip Gambel

#9/A
GND
2/5/03

Filed: January 31, 2001

Title: TREATMENT OF CELL MALIGNANCIES USING COMBINATION OF B CELL DEPLETING ANTIBODY AND IMMUNE MODULATING ANTIBODY...

* * * * *

AMENDMENT AND REPLY

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated July 2, 2002, please enter and consider the following amendments and remarks.

IN THE SPECIFICATION:

The specification is amended as described below, to correct minor informalities:

1. The paragraph beginning on page 1, line 24, is replaced with the following paragraph, in which "Rixtimab" is replaced with "Rituximab,"and "C2B" is replaced with "C2B8, and "No's" is replaced with "Nos.":

-- In fact, a chimeric anti-CD20 antibody, RITUXAN® (also known as Rituximab, MabThera®, IDEC-C2B8, and C2B8) is the first FDA approved monoclonal antibody for treatment of cancer (non-Hodgkin's lymphoma) and was developed by IDEC Pharmaceuticals Corporation (see US Patent Nos. 5,843,439; 5,776,456; and 5,736,137). --

a1

---

2. The paragraph beginning on page 14, line 1, is replaced with the following paragraph, in which "<<1311" is replaced with ""^{131}I ":